Literature DB >> 12466974

Deregulation of cyclin E2 expression and associated kinase activity in primary breast tumors.

Marc Payton1, Shelia Scully, Grace Chung, Steve Coats.   

Abstract

The increased expression of G(1) cyclins has been associated with the many types of human tumors. In primary solid tumors however, the expression and activity of cyclin E2, the newest member of the G(1) cyclin family, is largely unknown. In this study we have analysed the expression of the E-type cyclins in primary solid tumors from breast, lung, uterus, ovary, colon, and rectal tissues. Relative gene expression was analysed by quantitative real-time reverse transcription polymerase chain reaction (Taqman). The levels of cyclin E1 and cyclin E2 were significantly elevated (23 vs 38%, respectively) in primary breast tumor samples relative to normal breast tissue controls. We also observed an inverse correlation between the expression of cyclin E1/E2 and estrogen receptor in breast tumors. Our results demonstrate that the expression and associated catalytic activity for both cyclin E1 and cyclin E2 is elevated in primary breast tumors when compared to normal breast tissue. The increased level of cyclin E2 in breast tumors suggests that, similar to cyclin E1, it may contribute to the pathogenesis of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466974     DOI: 10.1038/sj.onc.1206035

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

1.  Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes.

Authors:  Sharmistha Pal; Sheethal N Vishwanath; Hediye Erdjument-Bromage; Paul Tempst; Saïd Sif
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

2.  The p110 isoform of the CDP/Cux transcription factor accelerates entry into S phase.

Authors:  Laurent Sansregret; Brigitte Goulet; Ryoko Harada; Brian Wilson; Lam Leduy; Jacques Bertoglio; Alain Nepveu
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

Review 3.  Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer.

Authors:  David N Danforth
Journal:  Breast Cancer (Auckl)       Date:  2016-08-17

4.  The Role of MicroRNAs and Human Epidermal Growth Factor Receptor 2 in Proliferative Lupus Nephritis.

Authors:  Patrícia Costa-Reis; Pierre A Russo; Zhe Zhang; Lucrezia Colonna; Kelly Maurer; Stefania Gallucci; Steffan W Schulz; Adnan N Kiani; Michelle Petri; Kathleen E Sullivan
Journal:  Arthritis Rheumatol       Date:  2015-09       Impact factor: 10.995

5.  Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer.

Authors:  C Elizabeth Caldon; Elizabeth A Musgrove
Journal:  Cell Div       Date:  2010-01-17       Impact factor: 5.130

6.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20

7.  Breast cancer biomarker discovery in the functional genomic age: a systematic review of 42 gene expression signatures.

Authors:  M C Abba; E Lacunza; M Butti; C M Aldaz
Journal:  Biomark Insights       Date:  2010-10-27

Review 8.  Genetics of breast cancer bone metastasis: a sequential multistep pattern.

Authors:  Hassan Fazilaty; Parvin Mehdipour
Journal:  Clin Exp Metastasis       Date:  2014-02-04       Impact factor: 5.150

Review 9.  A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy.

Authors:  S Mazumder; E L DuPree; A Almasan
Journal:  Curr Cancer Drug Targets       Date:  2004-02       Impact factor: 3.428

10.  Inhibition of E2F1 activity and cell cycle progression by arsenic via retinoblastoma protein.

Authors:  Lynn A Sheldon
Journal:  Cell Cycle       Date:  2017-09-28       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.